Plexxikon is a biotechnology company focused on developing targeted therapies for cancer and other serious diseases. Founded in 2001, it utilizes a proprietary platform to discover and optimize small molecule drugs that can specifically inhibit disease-causing proteins. The company is known for its innovative approach to drug discovery, which includes collaborations with major pharmaceutical companies. One of its notable products is Zydelig, a drug approved for certain types of blood cancers. Plexxikon aims to improve patient outcomes through precision medicine and advanced research techniques.